myeloproliferative disease

The test runs on Qiagen's Rotor-Gene Q MDx system and is designed to qualitatively detect the JAK2 V617F/G1849T allele in genomic DNA from whole blood.

The study expands on the known genetic subtypes, shows that they are correlated with clinical outcome, and paves the way for better subtype-driven patient management. 

A multistage GWAS suggests inherited SNPs at four sites in the genome can contribute to the risk of developing myeloproliferative neoplasms.

Researchers have found that the order in which TET2 and JAK2 mutations are acquired may impact drug response and disease progression.

The 95-gene test is for detecting leukemia, myelodysplastic syndromes, and myeloproliferative disorders and can return results in less than one week.

Qiagen said this week that it has signed an agreement with Eli Lilly to develop a companion diagnostic for an early-stage compound that Lilly is developing to treat blood cancer.

By Turna Ray
Qiagen and Eli Lilly have partnered to develop and commercialize a molecular diagnostic that will help pick out best responders to a blood cancer drug that is in early development in Lilly's pipeline.

The Leukemia and Lymphoma Society grant will fund genome-wide analysis research.

The acquisition will also bolster Qiagen's personalized medicine play through the addition of Ipsogen's extensive portfolio of personalized diagnostics and prognostics in the area of blood cancer.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.